Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers

Launched by HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY · May 17, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how two natural substances, Urolithin A (UA) and Fisetin, might help improve sleep quality and important markers of aging in middle-aged and older adults. Researchers want to find out if these substances can make a difference in how well people sleep and in reducing signs of aging, like inflammation and oxidative stress. Participants will be assigned to one of four groups: one group will take a placebo (a pill with no active ingredients), while the others will take different doses of UA and Fisetin.

To be eligible for the trial, you need to be between 45 and 70 years old and experience some sleep difficulties, as indicated by a specific sleep quality questionnaire. Participants will take the capsules daily for 12 weeks, attend three clinic visits, and complete various assessments about their sleep and health. They will also keep a sleep diary and provide samples for further analysis. This study aims to gather evidence that could lead to new ways to promote healthy aging through nutrition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 45-70 years;
• • Total score \> 5 points on the Pittsburgh Sleep Quality Index (PSQI) for sleep quality assessment;
• • Able to use personal mobile devices for WeChat, internet access, and related operations;
• • Informed about the intervention trial and willing to undergo sleep monitoring and other examinations during the study;
• • Commitment to consume coffee, strong tea, or alcohol ≤1 time per week during the trial period;
• Exclusion Criteria:
• • Participation in any clinical trials or dietary/exercise intervention programs within the past 3 months or concurrently;
• • Diagnosis of major mental disorders or family history thereof, or current use of psychotropic drugs or mood-regulating medications;
• • Experiencing major psychological trauma (e.g., death of a close relative, significant financial loss) personally or within the family in the past 3 months;
• • Severe diseases affecting inflammatory levels and/or endocrine components (e.g., severe obesity, uncontrolled diabetes or poorly controlled blood glucose, myocardial infarction, cerebral infarction);
• • Current use of hormonal medications, beta-blockers, steroids, non-steroidal anti-inflammatory drugs (NSAIDs), etc.;
• • Use of medications potentially affecting sleep or aging biomarkers (e.g., melatonin, antidepressants, anxiolytics) within the past 3 months;
• • Plans for relocation or long-term travel within the next 6 months, which may hinder continuous intervention and follow-up.